Compare Fiverr International Ltd (FVRR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Merck & Co., Inc. — how do they compare? Fiverr International Ltd trades at $11.79 (market cap $404.45M), while Merck & Co., Inc. trades at $128.51 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 754.8× Fiverr International Ltd's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | MRK | |
|---|---|---|
Market Cap | $404.45M | $305.29B |
Sector | Industrials | Health |
52-Week High | $26.67 | $129.52 |
52-Week Low | $9.62 | $77.60 |
Enterprise Value | $135.05M | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.82, up 6.78% in the last session, showing strong momentum despite recent volatility. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, revenue grew to $430.91M in 2025 with improving net margins, while valuation ratios like P/E of 14.61 and P/S of 0.97 suggest potential undervaluation. Recent news highlights Fiverr's upcoming Q2 2026 earnings report on July 29, 2026, amid mixed sentiment from financial media.
The outlook for FVRR hinges on execution of its strategic shift and Q2 earnings performance. Opportunities include attractive valuation multiples and operational cash flow growth, but risks involve declining active buyers and ongoing legal investigations. Analyst consensus leans neutral with 41% buy ratings, reflecting cautious optimism pending clearer business traction.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
